A method for determining a prognosis of idiopathic pulmonary fibrosis, comprising the following steps (a) to (c): (a) a step of detecting an amount of at least one protein selected from S100A4, CIRP, and 14-3-3γ for a biological sample separated from the test subject; (b) a step of comparing the amount of the protein detected in the step (a) with a standard amount of the protein; and (c) a step of determining that the prognosis of idiopathic pulmonary fibrosis of the test subject is poor in a case where as a result of the comparison in the step (b), the amount of the protein in the test subject is higher than the standard amount.

Methods, kits, and active ingredients for diagnosing or treating arthritis or a degenerative disease of the skeletal system, or for selection of subjects for therapy. The methods for diagnosing arthritis involve the detection of an autoantibody, which is associated with arthritis, or excluding the presence of an autoantibody against collagen II. The methods for diagnosing a degenerative disease of the skeletal system, involve the detection of an autoantibody against thrombospondin-4 or COMP. The kits contain a detection agent for an autoantibody and can be used for diagnosing arthritis or a degenerative disease of the skeletal system. The active ingredient can be used for treating or preventing autoimmune-associated arthritis.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

Implant related risk of revision not caused by an infection or metal on metal reaction can be addressed by the methods provided herein, including diagnosing implant related risk of revision, use of kits for such diagnostic purposes and compositions for use in the treatment of implant related risk of revision, in particular implant related risk of revision not caused by an infection or metal on metal reaction.

Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

The precision of a lateral flow assay for determining the concentration of an analyte in the plasma fraction of a sample of whole blood can be significantly improved by applying an integrated step for determining the hematocrit of the optionally diluted sample, and taking both hematocrit and dilution factor into account when calculating the concentration of the analyte. This is made possible inter alia by using a predetermined wavelength when taking an image of the sample after application to a substrate in the lateral flow assay device, and wherein said wavelength is selected based on the dilution factor used. This hematocrit measurement is advantageously integrated in lateral flow assay methods and devices for the measurement of an analyte in plasma and contributes significantly to an improved precision of such assays.

Disclosed herein are immunoassay methods for detecting and quantifying human neutrophil elastase (HNE) generated fragments of calprotectin in a biofluid sample; and monoclonal antibodies and assay kits for use in such methods. The methods may be used for detecting, monitoring and/or determining the status or severity of a disease characterized by or exhibiting inflammation in a patient.

The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation of S100A9 in the body of a subject at sites of inflammation, using in vivo non-invasive molecular imaging techniques for the detection of said compounds. Accordingly, labeled quinoline-3-carboxamide compounds can be applied to evaluate the risk of a subject of developing an inflammatory disease and to follow the progress of the disease.

An immunobiosensor is disclosed. The immunobiosensor is based on a membrane lateral flow immuno-chromatographic assay (LF-ICA). The immunobiosensor includes: a metal binding protein 10 whose conformation changes upon reaction with a metal ion 1 in a sample; a sensing antibody 20 reacting with the conformationally changed metal binding protein 10 as an antigen; a signal substance 30 conjugated with the metal binding protein 10 or the sensing antibody 20 to form a signal conjugate 30a or 30b; a signal generator 40 reacting with the signal conjugate 30a or 30b to generate a reaction signal; and a reaction strip 50 in the form of a porous membrane adapted to move the sample and where the antigen-antibody reaction occurs and the reaction signal is generated. Also disclosed is a sensor system including the immunobiosensor.